Interview: Evgeniy Gaydukov – Country Director, AstraZeneca Ukraine
Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the…
Address: London, England W1K 1LN,United Kingdom
Tel: 0207 604 8032
Web: http://www.astrazeneca.co.uk/home/
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013, it moved its headquarters to Cambridge, UK, and concentrated its R&D in three sites: Cambridge; Gaithersburg, Maryland, USA (location of MedImmune) for work on biopharmaceuticals; and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs.[5] AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation.[6]
The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group[7][8] (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). Since the merger it has been among the world’s largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
AstraZeneca has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.
Cardivascular medicine
Gastrointestinal medicines
Infection medicines
Oncology medicines
Neuroscience medicines
Respiratory and Inflammation medicines
Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the…
AstraZeneca reported decrease in its global revenue for the first half of 2011 mostly due to adverse market…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi…
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the…
Following on from our list of the overall top 10 companies in the Saudi Arabian pharma market, here PharmaBoardroom…
Japanese pharma companies are already far lower-profile than their occidental counterparts but an even lesser-known…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
The top 10 pharma companies in Saudi Arabia ranked by sales value in USD millions MAT Q1 2019. These top 10…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Japan’s pharma market is one of the world’s biggest, with a value of around USD 95 billion, according…